Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine for Hand-Foot Syndrome in Cancer Patients
NCT03173365Phase 2Terminated
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Jul 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Onreltea in hand-foot syndrome (HFS), sponsored by Heinrich Heine University Düsseldorf. Started Jul 2017; status: terminated.
02
Drugs
Onreltea
03
Conditions
hand-foot syndrome (HFS)
Beyond the preview
Go deeper on NCT03173365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173365.